The preparation of poly-2-oxazoline amphiphilic polymers and copolymers is described. Self-assembled particles comprising these amphiphilic polymers and which are useful for the targeted delivery of therapeutic and diagnostic agents are also described.

The preparation of poly-2-oxazoline amphiphilic polymers and copolymers is described. Self-assembled particles comprising these amphiphilic polymers and which are useful for the targeted delivery of therapeutic and diagnostic agents are also described.

The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for drug delivery, biodegradable consumer plastics, or solvents for Li-based batteries or supercapacitors. The invention is based, at least in part, on the discovery that poly(glyceric acid carbonate)s and alkyl functionalized poly(1,2 glycerol carbonates) and poly(glyceric acid carbonate)s and pharmaceutical agent/composition functionalized poly(1,2 glycerol carbonates) and poly(glyceric acid carbonate)s represent a new type of glycerol based polymer that 1) degrade into glycerol and carbon dioxide; 2) the poly(1,2 glycerol carbonates) degrade more readily than conventional poly(1,3 glycerol carbonates; and 3) poly(1,2 glycerol carbonates) can be processed to give melts, viscous fluids, liquids, films, sheets, gels, meshes, foams, fibers, or particles.

The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for drug delivery, biodegradable consumer plastics, or solvents for Li-based batteries or supercapacitors. The invention is based, at least in part, on the discovery that poly(glyceric acid carbonate)s and alkyl functionalized poly(1,2 glycerol carbonates) and poly(glyceric acid carbonate)s and pharmaceutical agent/composition functionalized poly(1,2 glycerol carbonates) and poly(glyceric acid carbonate)s represent a new type of glycerol based polymer that 1) degrade into glycerol and carbon dioxide; 2) the poly(1,2 glycerol carbonates) degrade more readily than conventional poly(1,3 glycerol carbonates; and 3) poly(1,2 glycerol carbonates) can be processed to give melts, viscous fluids, liquids, films, sheets, gels, meshes, foams, fibers, or particles.

The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.

The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.

A method for reversing immune suppression or immune exhaustion or for treating a disease associated with immune suppression includes: administering a composition to a subject in need of such treatments, wherein the composition contains a CD11b modulator that binds specifically to CD11b on a cell to inhibit PD-L1 expression. The CD11b modulator is an antibody or an antigen-binding portion thereof, or a compound as described.